Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Guangzhou Kingmed Diagnostics Group Co., Ltd. (603882.SS)
CNY28.04
+1.04 (+3.85%)
CN SHH Healthcare Medical - Diagnostics & Research
Address
No. 10, Helix 3rd Road 510000
Guangzhou, CN
Guangzhou, CN
CEO
Yaoming Liang
Website
kingmed.com.cn
IPO
2017-09-08
ISIN CNE100002VW1
Description
Guangzhou Kingmed Diagnostics Group Co., Ltd. operates as a prominent independent medical laboratory provider. Its extensive service portfolio encompasses a wide array of offerings, such as medical diagnostic information, clinical trial assistance, and comprehensive laboratory services. The company also specializes in food and hygiene testing, health management solutions, and medical cold chain logistics. Additionally, Kingmed engages in scientific research, develops in vitro diagnostics, and utilizes advanced capabilities in healthcare big data, artificial intelligence, and forensic testing. Operating a network of 37 state-of-the-art testing facilities, the company maintains a significant presence across both mainland China and Hong Kong. Established in 2003, its corporate headquarters are situated in Guangzhou, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY28.04
+1.04 (+3.85%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6M
Beta
0.45
Float Shares
297.65M
Free Float %
64.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.22% | -2.66% | -6.23% | -17.79% | -13.34% | -9.73% | -11.78% | -63.22% | -83.11% | +156.51% | +156.51% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
28.04
DCF (Unlevered)
17.73
-36.8%
DCF (Levered)
31.83
+13.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.52
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%-16.1% Q1'26: -7.9% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+54.9% ★ Q1'26: +250.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+5.1% Q1'26: -4.8% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-2.8% Q1'26: +4.8% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%-3.5% Q1'26: +4.2% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+0.7% Q1'26: +2.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×3.38× ★ Q1'26: 2.73× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 5 EPS Ana. |
Dec 2027 7 Rev. Ana. 6 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.79B
est: 4.05B (-6.4%)
|
4.53B
est: 5.06B (-10.6%)
|
5.27B
est: 6.49B (-18.8%)
|
8.24B
est: 8.22B (+0.2%)
|
11.94B
est: 11.18B (+6.8%)
|
15.48B
est: 15.65B (-1.1%)
|
8.54B
est: 8.25B (+3.5%)
|
7.19B
est: 7.56B (-4.9%)
|
6.03B
est: 6.17B (-2.3%)
|
6.26B
5.97B – 6.61B
+1.5% YoY
|
6.87B
6.15B – 8.13B
+9.7% YoY
|
7.61B
7.53B – 7.69B
+10.7% YoY
|
| EBITDA |
422.11M
est: 714.00M (-40.9%)
|
528.88M
est: 892.31M (-40.7%)
|
694.40M
est: 1.14B (-39.3%)
|
2.07B
est: 1.45B (+42.5%)
|
3.06B
est: 1.97B (+55.0%)
|
3.68B
est: 2.76B (+33.4%)
|
866.66M
est: 1.11B (-21.8%)
|
257.86M
est: 1.02B (-74.6%)
|
247.52M
est: 829.58M (-70.2%)
|
841.80M
802.22M – 887.73M
+1.5% YoY
|
923.39M
826.34M – 1.09B
+9.7% YoY
|
1.02B
1.01B – 1.03B
+10.7% YoY
|
| EBIT |
247.65M
est: 550.03M (-55.0%)
|
304.01M
est: 687.40M (-55.8%)
|
437.85M
est: 881.50M (-50.3%)
|
1.79B
est: 1.12B (+59.8%)
|
2.72B
est: 1.52B (+79.4%)
|
3.27B
est: 2.12B (+53.7%)
|
414.93M
est: 717.61M (-42.2%)
|
-180.92M
est: 657.47M (-127.5%)
|
-166.93M
est: 536.87M (-131.1%)
|
544.78M
519.16M – 574.50M
+1.5% YoY
|
597.58M
534.78M – 707.00M
+9.7% YoY
|
661.53M
654.58M – 668.49M
+10.7% YoY
|
| Net Income |
188.51M
est: 218.52M (-13.7%)
|
233.32M
est: 246.41M (-5.3%)
|
402.33M
est: 344.05M (+16.9%)
|
1.51B
est: 1.46B (+3.4%)
|
2.22B
est: 2.07B (+7.3%)
|
2.75B
est: 2.74B (+0.6%)
|
643.38M
est: 448.19M (+43.6%)
|
-381.24M
est: -416.07M (+8.4%)
|
-173.24M
est: -70.35M (-146.3%)
|
338.63M
251.62M – 440.70M
+581.4% YoY
|
514.43M
335.16M – 707.55M
+51.9% YoY
|
588.76M
434.38M – 687.77M
+14.4% YoY
|
| SGA |
972.15M
est: 776.62M (+25.2%)
|
1.07B
est: 970.57M (+10.3%)
|
1.22B
est: 1.24B (-2.3%)
|
1.54B
est: 1.58B (-2.2%)
|
2.32B
est: 2.14B (+8.4%)
|
2.51B
est: 3.00B (-16.5%)
|
1.73B
est: 1.43B (+20.6%)
|
1.53B
est: 1.31B (+16.4%)
|
586.01M
est: 1.07B (-45.4%)
|
1.09B
1.04B – 1.15B
+1.5% YoY
|
1.19B
1.07B – 1.41B
+9.7% YoY
|
1.32B
1.31B – 1.34B
+10.7% YoY
|
| EPS |
0.46
est: 0.47 (-2.1%)
|
0.51
est: 0.53 (-3.8%)
|
0.88
est: 0.74 (+18.9%)
|
3.29
est: 3.14 (+4.7%)
|
4.80
est: 4.45 (+7.9%)
|
5.90
est: 5.89 (+0.2%)
|
1.38
est: 0.96 (+44.3%)
|
-0.82
est: -0.86 (+5.0%)
|
-0.37
est: -0.15 (-153.5%)
|
0.75
0.54 – 0.94
+617.2% YoY
|
0.98
0.72 – 1.51
+30.2% YoY
|
1.23
0.93 – 1.47
+25.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
589.25M
OE per share TTM
1.28
Owner's Yield
4.84%
Maintenance CapEx ratio
307.66%
Maint CapEx / Avg PPE
20.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 30 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Franklin FTSE China ETF FLCH | 0.01% | 24.0K | 0.19% |
| 2 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 111.1K | 0.19% |
| 3 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 18.4K | 0.44% |
| 4 | Vanguard FTSE Asia ex Japan Shares Index ETF VAE.AX | 0.00% | 16.7K | 0.40% |
| 5 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 49.4K | 0.46% |
| 6 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 195.1K | 0.39% |
| 7 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 165.6K | 0.06% |
| 8 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 104.5K | 0.29% |
| 9 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 32.2K | 0.26% |
| 10 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 14.3K | 0.48% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-16.0K
Shares Outstanding
463.26M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hui Yuan Li | Deputy General Manager | — | male |
| Ji Ma | Deputy General Manager | — | male |
| Li Qin Zhou | Financial Director & Accounting Supervisor | — | female |
| Linglai Wang | Deputy GM, Secretary & Director | — | male |
| Ting Yan | Deputy GM & Director | — | female |
| Xiao Feng Ou Yang | Deputy GM & Director | — | male |
| Yaoming Liang | Chairman & GM | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603882.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
